engineered T-cell therapy (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameengineered T-cell therapy (Fred Hutchinson Cancer Research Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionMesothelin modulatorsWilms' Tumour 1 modulators
TargetsMesothelinWilms' Tumour 1
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFred Hutchinson Cancer Research Center
Active IndicationsN/A
Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A